



Diesse and Achilles Vaccines working together for new monoclonal antibody based therapies

Siena, 19 February 2021 – Diesse Diagnostica Senese and Achilles Vaccines today announced the signing of a strategic agreement under which Diesse develops diagnostics tests dedicated for monoclonal antibody therapeutics that Achilles Vaccines will develop.

"We are proud to provide Achilles Vaccines with our extensive experience in the development and design of diagnostic tests for the quantification of the immune response against pathogens. The next-generation of quantitative and rapid tests, developed in association with the dedicated therapeutics, will allow physicians to easily and accurately assess whether or not to deliver pharmacotherapy to patients" - states Massimiliano Boggetti, CEO of Diesse.

"The road to the mass use of monoclonal antibodies against known and unknown pathogens necessarily passes through two phases. The first is the drastic reduction of production costs. The second is the early diagnosis of infection through "companion" diagnostics. DIESSE's approach to this type of diagnostics is of fundamental value to us in terms of the development and production of therapeutics oriented towards the global market, including developing countries" - adds Riccardo Baccheschi, CEO of Achilles Vaccines.

This agreement between a biopharmaceutical company and a diagnostic company from the Siene area demonstrates the importance of combining complementary knowledge in the world of health. It will accelerate innovation and guarantee modern and effective treatments, achieving a real global impact.

Achilles Vaccines

Achilles Vaccines (AV) is a biotech company committed to developing vaccines and biopharmaceuticals which address some of the most critical health issues, including antibiotic resistance and emerging infectious diseases. Its goal is to produce safe and potent vaccines sustainably. The company uses innovative technology platforms centered on modified mOMVs (Outer Membrane Vesicles), an extensive network of international partners, and specialized expertise. The use of mOMVs in the vaccine field will be supported by the first



4.0 laboratory and the latest generation of Reverse Vaccinology, a technology that was developed, and which finds new areas of application, in Siena. AV has financed and coordinated the industrial development of mAbCo19, a hyper-potent monoclonal antibody against SARS-COV2, which emerged from Prof Rino Rappuoli's MAD Lab.

Diesse Diagnostica Senese S.p.A.

Diesse Diagnostica Senese S.p.A. is an Italian company which produces integrated and entirely in-house in-vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems mainly in the field of immunodiagnosics and automatic ESR measurement.

The company has a global presence in over 100 countries, has 3 production sites and 1 research center, where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, identifying Diesse as an example of real "Diagnostics Evolution".

Press Office:

Tatiana Zoppi – Diesse Diagnostica Senese

Tel.+39 348 3337827 – tatianazoppi@diesse.it

Chiara Angela Iosco – Achilles Vaccines

Tel. +39 3426653282 – c.iosco@achillecvaccines.com